The Hungarian life sciences, medical technology, and biotechnology sectors represent a highly concentrated, export-driven industry defined by a strong academic foundation and a transition from traditional pharmaceutical manufacturing to advanced digital health, medical deep tech, and artificial intelligence. The sector comprises approximately 150 to 180 export-driven medical device manufacturing enterprises, alongside around 90 biotechnology companies and a broader network of

The European healthtech and medtech sectors have entered a phase of disciplined maturity, transitioning away from the venture subsidised experimentation of the early 2020s toward an era characterised by industrialisation and regulatory Darwinism. In the current market environment of 2025 and 2026, the criteria for a successful Series A funding round have shifted fundamentally. Investors no longer prioritise raw user acquisition or speculative growth; instead, they demand a ri